Promoting PTEN expression in CRC cell lines will stop the activation of the phosphatidylinositol-3-kinase (PI3K)/sinkserine/threonine kinase (Akt) signaling pathway, which affects CRC cell growth, promotes apoptosis, and improves sensitivity to targeted therapy, immunotherapy, and conventional therapy. This evidence concerns the gene AKT1 and colorectal carcinoma.